From the Blogosphere
Cloud Platforms: The Crucial Foundation | @CloudExpo #IoT #Microservices
How a cloud environment can offer the flexible resources, elastic scalability and system reliability
By: Brian Daleiden
Dec. 19, 2015 02:00 AM
Cloud Platforms: The Crucial Foundation to Safeguard the Pharmaceutical Supply Chain
In today's pharmaceutical supply chain, counterfeit activity is thriving. As pharma companies have expanded target markets and outsourced production over the last decade, the supply chain has become increasingly global, virtual, and vulnerable. Illicit activity has thrived, and patients have suffered, with hundreds of thousands dying each year from counterfeit and contaminated drugs.
More than 40 countries have responded with new laws that regulate prescription medications as they travel through the supply chain. While this is a quantum leap forward for patient health, the implications for supply chain stakeholders, from pharmaceutical companies and their contract manufacturing partners to the pharmacies that serve patients are daunting: they must master each country's disparate track and trace requirements; create a system architecture capable of generating, managing, and storing what will be unprecedented volumes of regulated data; and figure out how to efficiently exchange that data with hundreds to tens of thousands of direct and indirect supply chain partners.
In the process, traditional technology will be put to the test. Traditional, on-premises data center and enterprise software infrastructure will prove incapable of meeting the enormous data management and transactional processing demands that compliance will introduce. Cloud computing networks offer the only practical solution for this challenge.
This article will discuss the how a cloud environment can offer the flexible resources, elastic scalability and system reliability required to meet compliance regulations and patient safety protections necessitating the tracking and tracing of medications through every step of the supply chain.
From Local to Global: Increasingly Virtual and Vulnerable
Many have built relationships with local contract manufacturers, pharmaceutical companies and third-party logistical organizations for production and distribution efficiencies. These partnerships have allowed them to decrease fixed costs, improve agility and enhance access to the global market by cost-effectively producing and distributing product around the world. This growth creates vulnerability as a longer supply chain with more changes of possession and ownership from drug manufacturing to patient dispensation creates more opportunity for counterfeiting and diversion.
The true scope of counterfeiting - which encompasses everything from inactive or incorrect ingredients to drugs with high levels of contaminants or fake packaging - is unknown, but the World Health Organization (WHO) estimates that between 1% and 10% of drugs sold around the world are impacted, and the overall worldwide sale of counterfeit drugs is valued at more than $75 billion a year. The cost to patient safety: immense.
The Response: Track and Trace Regulation
For the industry, however, these diverse regulations introduce a web of challenges. While most regulations involve some combination of generating and managing serial numbers for each unit of drug product, tracking product through the supply chain, verifying data and transactions at various points in the network, and reporting associated events to government authorities, no two countries in the world have passed the same requirements or mandated the same information formats. This is particularly problematic when you consider that globally tens of billion units of drug product are produced and distributed annually across a global supply network made up of well over one million members.
Global Track and Trace Breaks Traditional Enterprise Approaches
The network challenges are just as daunting. A mid-sized company may use a dozen or more contract partners to augment internal sites to produce their serialized products for different markets. All of these sites and their different serialization line management systems need to be integrated with across multiple transactions. Even more difficult are the downstream network connection challenges. Dozens to hundreds of direct trading partners, including wholesale distributors, repackagers and dispensers need to be connected for lot-level traceability and serialized product data exchange as products are sold, distributed, returned and verified during investigations. Add in the requirement to receive and respond to serialized product verification requests from thousands of indirect trading partners such as independent pharmacies and the pharmaceutical manufacturer faces an unprecedented challenge. This intricate, highly connected serialized supply network will now need high performance electronic connections over which millions of transactions and gigabytes of compliance data will flow.
The U. S. DSCSA example is just one of the many scenarios facing multi-national pharmaceutical companies. All in all, an in-house infrastructure to support this network ecosystem would be prohibitively expensive and complicated from a capital, personnel, and expertise perspective. Because of the dynamic nature of global track and trace regulations, companies making large capital investments in their physical IT infrastructure also take on unacceptable risks as regulatory environments and their related data management requirements may change on a yearly or even quarterly basis. Given the volume and complexity of required partner connections, an individual, point-to-point approach built upon traditional enterprise infrastructures using standard SQL database is just not feasible. This is why Life Sciences must look to the cloud for a solution.
Network-based Cloud Platforms Are the Only Way to Meet Emerging Needs
Cloud computing infrastructures such as Amazon's AWS Cloud, utilizing global, on-demand data and transaction processing resources, ticks all of the requisite boxes. Yet, cloud environments come in several different flavors, so it's important to understand which design and configurations will meet emerging challenges facing the industry.
Public vs. Private
Single, Multi-, and Network-Tenant Environments
A single-tenant architecture is a legacy approach that creates a separate software instance and supporting infrastructure for each customer and their data. This type of architecture will not support sharing compliance data with many partners or evolving regulations which necessitate regular updates.
In a multi-tenant setup, a single instance of software and the infrastructure serves multiple parties. Multi-tenancy is a step forward from single tenancy, but it does not explicitly facilitate connectivity and communication between companies.
Network-Tenancy for Mission-Critical Life Sciences
The fundamental purpose of a network-tenant environment is to enable interactions and share business processes across multiple companies on the network, establishing a new dimension of collaboration with existing partners and allowing for discoverability of new partners within a directory structure.
In a network-tenant solution, interactions with other companies are a paved road and a singular process: you integrate into the network once, and can then interact with everyone. Network tenancy also provides data translation and transportation, enabling seamless information exchange in a regulatory world with incomplete standards and diverse corporate data preferences. Think of it like the Interstate highway or the electrical grid ensuring free flow across the network while enabling diverse entities to join.
Service providers distribute software updates to all network residents simultaneously, insuring that all companies remain in compliance as regulations continue to evolve. Network tenancy builds on the security protocols of multi-tenancy, protecting data and the private network interactions while enhancing interoperability and business growth by adding new forms of public discovery and inquiry across the network similar to those seen in consumer networks like LinkedIn. Well-defined network tenant platforms add additional layers of security by invoking a rigorous process of vetting new members prior to adding them to the network.
Specifically for Life Sciences, network tenant platforms must go one step further. The systems deployed must be designed to meet regulatory requirements in areas like validation while ensuring overall system integrity and reliability as critical medicines are produced and distributed. The platform and the processes used to build solutions on the platform must minimize and isolate change that impact validated systems while providing detailed IQ and OQ artifacts to support validation testing on new platform releases. In addition, inherent fail-over and redundancy must be designed in from the start for both data management and transaction processing.
Done right, network tenancy enables residents to share compliance-related business processes with diverse global supply and trading partners; seamlessly exchange data in a world without format standards; accommodate the massive scale demands of global serialization; and grow their businesses by supporting global supply relationships and discovery of new prospective partners. It also lays the foundation for new business value as any one network member now has global connection and reach to leverage for new forms of supply planning and patient engagement. It is the only solution that can accommodate the evolving needs of the fast growing Life Sciences supply chain.
Choosing the Right Solution for Success
As outlined here, a public, network-tenant cloud environment that offers flexible interoperability and global elasticity will support businesses as they roll-out serialization and track and trace solution. It will make connecting with global trade partners and exchanging data as simple as integrating to the platform once, and then interoperating with everyone. It will create a global network for collaboration and enable the smallest emerging biopharma or street corner pharmacy to enjoy the same global computing firepower and capabilities as the largest global pharmaceutical company.
The right platform will also level the playing field in terms of technical resources will support tighter financial accountability. Most importantly, though, the right networked-cloud environment is the only way to comprehensively track medications through every step of the supply chain, and truly protect patient safety.
Reader Feedback: Page 1 of 1
Latest AJAXWorld RIA Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week